Acinetobacter baumannii resistant to everything: What should we do?

Clinical Microbiology and Infection

Volumn 17, Issue 7, 2011, Pages 955-956

  Vila, J ^a   Pachon J ^b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY OF SEVILLE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAPENEMASE; CEFTOBIPROLE; CEPHALOSPORINASE; COLISTIN; DORIPENEM; RIFAMPICIN; TIGECYCLINE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACTERIAL MUTATION; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIUM ISOLATE; DRUG MEGADOSE; GENE INSERTION; NONHUMAN; NOTE; PREVALENCE; PRIORITY JOURNAL;

ACINETOBACTER BAUMANNII;

EID: 79960023275     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2011.03566.x     Document Type: Note

References (6)

1. Espinal P, Roca I, Vila J. Clinical impact and molecular bases of antimicrobial resistance in non-baumannii Acinetobacter. Future Microbiol 2011; 6: 495-511.
2. Pachón J, Vila J. Treatment of multiresistant Acinetobacter baumannii infections. Curr Opin Investig Drugs 2009; 10: 150-156.
3. Vila J, Martí S, Sánchez-Céspedes J. Porins, efflux pumps and multidrug resistance in Acinetobacter baumannii. J Antimicrob Chemother 2007; 59: 1210-1215.
4. Plachouras D, Karvanen M, Friberg LE et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother 2009; 53: 3430-3436.
5. Martínez JL, Rojo F, Vila J. Are non-lethal targets useful for developing novel antimicrobials? Future Microbiol 2011; in press.
6. McConnell MJ, Pachón J. Active and passive immunization against Acinetobacter baumannii using an inactivated whole cell vaccine. Vaccine 2011; 29: 1-5.